NanoLogix, Inc., formerly known as Infectech, Inc., is a technology application innovator of biogas
products and services designed to assist in worldwide energy independence and
reduce pollution from renewable, environmentally-friendly energy sources.
NanoLogix is also engaged in the research and development of diagnostic test
kits designed to be used for the rapid identification of infectious human
diseases. The Company's patents span the identification and antibiotic
sensitivity testing of 34 disease-producing bacteria, including M.
tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and
nocardia. These bacteria are cited as prominent causes of morbidity and
mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally,
NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer
cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a
genetically based induction of "cell suicide" in cells.